BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitisBristol-Myers Squibb’s commercial hopes for new multiple sclerosis drug Zeposia have yet to bear fruit thanks to the Share XBMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitishttps://pharmaphorum.com/news/bms-eyes-may-fda-verdict-for-ms-drug-zeposia-in-ulcerative-colitis/
NICE rejects BMS’ Zeposia MS pill in provisional guidanceNICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing Share XNICE rejects BMS’ Zeposia MS pill in provisional guidancehttps://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/
Data sets up ulcerative colitis expansion for BMS’ MS drug ZeposiaBristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – Share XData sets up ulcerative colitis expansion for BMS’ MS drug Zeposiahttps://pharmaphorum.com/news/data-sets-up-ulcerative-colitis-expansion-for-bms-ms-drug-zeposia/
BMS launches COVID-19 delayed MS drug Zeposia in USBristol-Myers Squibb opted not to launch its new multiple sclerosis therapy Zeposia when it got FDA approval in Share XBMS launches COVID-19 delayed MS drug Zeposia in UShttps://pharmaphorum.com/news/bms-launches-covid-19-delayed-ms-drug-zeposia-in-us/
